3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
50
Breast Neoplasms
25
Neoplasms
6
Neoplasm Metastasis
3
Prostate Adenocarcinoma
2
Breast Neoplasms, Male
2
Advanced Breast Cancer
2
Recurrence
1
Primary Ovarian Insufficiency
1
PSA Level Greater Than Two
1
Osteitis Deformans
1
Lymphatic Metastasis
1
Infertility
1
Hormone-sensitive Metastatic Breast Cancer
1
Hormone Sensitive Prostate Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Advanced Metastatic Breast Cancer
1
Interventions
Alpelisib
4
berzosertib
3
Fulvestrant
3
Everolimus
3
parsaclisib
2
Topotecan
2
NVP-BKM120
2
Cetuximab
2
talazoparib
1
sotorasib
1
serabelisib
1
ruxolitinib
1
duvelisib
1
dapagliflozin
1
cobimetinib
1
ceralasertib
1
binimetinib
1
avelumab
1
Vemurafenib
1
SF 1126
1
Rituximab
1
Paclitaxel
1
Oxaliplatin
1
Leuprolide
1
Leucovorin
1
Letrozole
1
Irinotecan
1
Goserelin
1
Fluorouracil
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Hereditary Sensory and Autonomic Neuropathies
×
Goserelin
×
Clear all
NCT03056755
2026-01-13
BYLieve
Novartis
Phase 2
Completed
383 enrolled
16 charts